Anti-Cancer MAbS Market Outlook Highlights The Next Major Growth Opportunities
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Anti-Cancer MAbS Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for anti-cancer monoclonal antibodies has experienced robust expansion in recent years. Its value is projected to rise from $71.25 billion in 2025 to $78.12 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.6%. This historical growth has been driven by factors such as the increasing global prevalence of cancer, the demonstrated clinical effectiveness of mAbs, substantial investment in oncology research and development, the approval of biologic therapies by regulatory bodies, and improvements in survival rates achieved through cancer treatment.
The market for anti-cancer monoclonal antibodies is anticipated to experience robust expansion over the coming years, reaching a projected value of $112.41 billion by 2030, which corresponds to a compound annual growth rate (CAGR) of 9.5%. This forecasted growth is driven by several key factors, including the increasing adoption of personalized cancer treatments, the broader availability of biosimilar mAbs, heightened healthcare spending specifically for oncology, continuous progress in antibody engineering technologies, and enhanced access to biologic therapies. Prominent trends shaping this period involve a growing preference for targeted immunotherapies, the wider utilization of humanized and bispecific antibody formats, greater integration of combination cancer therapies, a heightened emphasis on precision oncology approaches, and the ongoing improvement of scalable manufacturing processes for these antibodies.
Download A Free Sample Report For Comprehensive Market Insights:
Anti-Cancer MAbS Market Growth Drivers And Industry Catalysts
The global rise in cancer incidence is anticipated to fuel the expansion of the anticancer monoclonal antibodies market moving forward. Cancer encompasses a range of disorders marked by uncontrolled cell proliferation that can invade and damage healthy tissues. This growing prevalence is driven by factors such as aging populations, shifts in lifestyle, environmental exposures, and improved diagnostic technologies that enhance detection rates. Anticancer monoclonal antibodies (mAbs) are engineered to target specific proteins on cancer cells, employing genetically modified versions of natural immune antibodies to identify and eliminate these cells; hence, a higher cancer prevalence boosts demand for the anticancer mAbs market. For example, as reported in February 2024 by the World Health Organization (WHO), a United Nations agency based in Switzerland, new cancer cases are expected to surpass 35 million by 2050, reflecting a 77% increase from the estimated 20 million cases recorded in 2022. Consequently, the worldwide surge in cancer prevalence is accelerating growth within the anticancer mAbs market.
Anti-Cancer MAbS Market Segments: Where Are The Largest Growth Opportunities?
The anti-cancer mabs market covered in this report is segmented –
1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types
2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications
3) By End User: Hospitals, Research Institutes, Other End Users
Subsegments:
1) By Murine Antibodies: Murine IgG, Murine IgM, Other Murine Isotypes
2) By Chimeric Antibodies: Chimeric IgG, Chimeric IgM, Other Chimeric Isotypes
3) By Humanized Antibodies: Humanized IgG, Humanized IgM, Other Humanized Isotypes
4) By Other Types: Fully Human Antibodies, Bispecific Antibodies, Conjugated Antibodies, Other Novel Formats
Anti-Cancer MAbS Market Trends Influencing Long-Term Demand
Leading players in the anti-cancer monoclonal antibodies (mAbs) market are concentrating on creating advanced approaches, including early-phase clinical trials, to progress new therapeutic candidates and boost their market edge. Clinical trials are organized research efforts using human subjects to assess safety, dosage, and treatment effectiveness of novel medical interventions like targeted antibodies and radioimmunotherapies. As an example, in April 2023, Y-mAbs Therapeutics Inc., a clinical biopharmaceutical company based in the US, initiated a Phase I clinical trial exploring GD2-SADA, a pre-targeted radioimmunotherapy aimed at GD2-positive solid tumors such as small cell lung cancer, sarcoma, and malignant melanoma. This therapy employs a two-step process: first, the SADA protein binds selectively to tumor cells expressing GD2; then, the radioactive ligand 177Lu-DOTA is administered, attaching to the SADA protein to provide focused radiation. The goal is to achieve maximum tumor cell damage while reducing radiation exposure to healthy tissue.
Anti-Cancer MAbS Market Major Participants And Competitive Dynamics
Major companies operating in the anti-cancer mabs market are Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Merck & Co. Inc., Spectrum Pharmaceuticals Inc., AstraZeneca plc., Pfizer Inc., Gilead Sciences Inc., Bayer HealthCare, ImmunoGen Inc., Genentech Inc., AbbVie Inc., Takeda Pharmaceuticals, Seattle Genetics, Regeneron Pharmaceuticals, Celgene, Ipsen, Daiichi Sankyo, ADC Therapeutics, MacroGenics Inc., Zymeworks Inc.
Access The Complete Anti-Cancer MAbS Market Report:
Anti-Cancer MAbS Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the anti-cancer MAbS market in 2025. Asia-Pacific is expected to be the fastest-growing region in the anti-cancer MAbS market during the forecast period. The regions covered in the anti-cancer mabs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
